Panthera Biopartners has completed a Series A funding round with Gresham House Ventures as a major investor. The capital raised will enable Panthera to further build out its network of clinical trial sites across the UK and overseas and increase its team of clinical trial experts in serving both pharma and patients.

Panthera Biopartners has completed a Series A funding round with Gresham House Ventures as a major investor. The capital raised will enable Panthera to further build out its network of clinical trial sites across the UK and overseas and increase its team of clinical trial experts in serving both pharma and patients.

Dublin start-up FoodMarble has raised €1.2M in a funding round which included HBAN business angels from the MedTech syndicate who invested alongside Enterprise Ireland, SOSV and Delta Partners. The investment will support the company's ongoing research and development, along with expansion into the US and Canada.

Deepbridge Capital and Boundary Capital backed diagnostics firm Glyconics® has been awarded an internationally recognised quality certification for the development of its diagnostic medical devices product range.

Ceryx Medical, a bioelectronics startup working towards the world’s first curative therapy for heart failure, has secured a £575,000 seed round.

The funding, which comprises a £250,000 commitment from the Development Bank of Wales, £225,000 from angel investors, and £100,000 from the University of Bristol’s Enterprise Investment Fund, managed by leading UK university spinout investor ParkWalk, will enable the company to grow its management and technology teams.

The Advanced Therapy Treatment Centre (ATTC) network has been awarded a total of £9.5 million to fund an additional 12 months of the programme. £6.5 million has been granted from the Government's Department for Business, Energy and Industrial Strategy (BEIS) and an additional £3 million from its Industrial Strategy Challenge Fund (ISCF), managed by UK Research and Innovation (UKRI). The funding will support additional initiatives through to March 2022 and continuation of certain centre and network projects which were impacted by the COVID-19 pandemic. This award builds upon the significant success of the ATTC network to date. The UK accounts for 12% of global advanced therapy medicinal product (ATMP) clinical trials and the network supports half of those.

Crista Galli Ventures, a new early-stage healthtech fund that offers patient capital and deep healthcare expertise, has launched this week.  Crista Galli Ventures partners with early-stage founders at Seed and Series A to build world-leading companies, and has tailored its strategy to the needs of ambitious healthtech entrepreneurs, and the unique industry in which they operate.

UK-based start-up Skin Analytics has raised £4 million in Series A funding. The funding round was led by Hoxton Ventures with participation from Nesta and Mustard Seed Ventures.

Asklepios BioPharmaceutical, Inc., a leading, clinical-stage gene therapy company dedicated to developing adeno-associated virus (AAV) gene therapies for genetic disorders, has been awared a £1.99m R&D Grant from Scottish Enterprise.

AskBio will invest £3.4m alongside the grant to fund research into the manufacturing challenges associated with scaling gene therapies for widespread patient access, to further develop technologies to improve the safety and efficacy of current therapies, and to enable the treatment of genetic diseases with more complicated disease pathways that the industry is not yet able to address.

ClinSpec Diagnostics, a university spin-out which has developed a way to detect cancer at an early stage using a simple blood test, has completed a £2.4m funding round led by Mercia’s EIS funds.

Medefer, the b2b virtual healthcare provider that is reimagining the old-fashioned outpatient system, has announced a £10m funding round led by private investment firm Nickleby Capital. The growth funding will be used to invest in people and technology to service new contracts, enable new product development and ensure scalable and robust growth from its strong pipeline. The company, founded by NHS consultant Dr Bahman Nedjat-Shokouhi - who still works in the NHS - has been recognised as one of the top 100 most exciting digital health companies in the UK, by the DTI.   

A healthtech business with an app that helps patients communicate with clinicians remotely has raised a further £2m to help expand its use.

Advanced Digital Innovation (ADI) has raised funding from NPIF – Mercia Equity Finance, which is managed by Mercia and is part of the Northern Powerhouse Investment Fund, the UK government’s Future Fund and the company’s Chair and founder Bob Gomersall.